Penumbra Stock - Analyst and earnings outlook as consensus settles

Penumbra stock draws attention ahead of its next earnings release, with Wall Street estimates and recent rating actions framing expectations for the medical device maker focused on neurovascular and vascular interventions.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 20:45 UTC. Details in the imprint.

Penumbra (US70975L1070) is drawing attention from analysts and investors as consensus expectations crystallize ahead of the medical device company's next earnings release. Recent broker commentary and estimate trends provide a structured view of how Wall Street values the stock.

What analysts currently expect

Penumbra last reported quarterly results for the period ended 03/31/2026 with revenue continuing to grow in its neurovascular and vascular product lines, according to the company’s latest earnings release. IR materials provide the detailed figures.

For the current fiscal year, Wall Street on average expects Penumbra to deliver solid double-digit revenue growth and an improvement in earnings per share compared with the prior year, based on consensus data compiled by major financial platforms.

How broker ratings are distributed

The analyst community remains broadly constructive on Penumbra stock, with a majority of firms rating the shares at Buy or an equivalent positive stance, complemented by a smaller number of Hold views. Market data services summarize the rating distribution.

Target prices published by covering banks frame an upside scenario relative to the recent trading range, while also reflecting execution risks in competitive neurovascular and vascular markets.

The product behind the stock

Penumbra generates most of its revenue from minimally invasive devices used to remove blood clots or restore blood flow in the brain and peripheral vessels, including aspiration-based thrombectomy systems, catheters and related technologies for stroke and embolism treatment.

Where the stock trades today

Penumbra shares trade on the New York Stock Exchange at $X.XX as of 06/21/2026, 20:45 UTC.

Key facts on Penumbra stock

• Company: Penumbra Inc.
• ISIN: US70975L1070
• WKN: A2P2KV
• Ticker: PEN
• Venue: NYSE
• Price (as of 06/21/2026, 20:45 UTC): X.XX USD
• Market cap: X,XXX,XXX,XXX USD (as of 06/21/2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.